Trial Profile

Phase Ib/IIa Dose Escalation and Expansion Study of [212-Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 212 Pb ADVC 001 (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; First in man
Acronyms TheraPb
Sponsors AdvanCell

Most Recent Events

08 Dec 2025 According to AdvanCell media release, the company completed Phase 1b dose escalation.
02 Dec 2025 According to AdvanCell media release, Enrollment for the TheraPb Phase 2 expansion is expected to commence initially at clinical sites in Australia, with planned expansion to sites in the United States in 2026.
02 Dec 2025 According to AdvanCell media release, the company announced the initiation of the Phase 2 expansion trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com